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Abstract Hypovitaminosis D represent an environmental
risk factors for cardiovascular (CV) disease. To investigate
the prevalence of hypovitaminosis D and the correlation
between GH/IGF-I deficiency and hypovitaminosis D with
CV risk in GH deficiency (GHD) patients. A link between
these hormones has been shown. Forty-one hypopituitaric
patients with GHD (22 males, age 18–84 years) and 41
controls were enrolled in the study. Anthropometric
parameters, blood pressure, glucose and lipid profile,
parathyroid hormone (PTH), 25(OH) vitamin D (vitamin
D), metabolic syndrome (MS), GH peak after GHRH ?
ARG, IGF-I, and standard deviation score (SDS) of IGF-I
(zIGF-I) were assessed. Vitamin D levels were lower in
patients than in controls (21.3 ± 12.3 vs. 28.2 ± 9.4,
p = 0.006). Deficiency was found in 51 % of patients
versus 14.6 % of controls (p\ 0.01), insufficiency in 26.8
versus 41.4 % (p = 0.269) and normal vitamin D levels in
21.9 versus 43.9 % (p = 0.060). The prevalence of dys-
lipidemia was 51.2 % in patients versus 12.1 % in controls
(p\ 0.001), type 2 diabetes mellitus (DM) was 7.3 versus
17 % (p = 0.292), hypertension was 44 versus 22 %
(p = 0.060), and MS was 17 versus 14.6 % (p = 0.957). In
patients, an association was found between the presence of
hypovitaminosis D and the prevalence of dyslipidemia,
hypertension and MS and between zIGF-I and the preva-
lence of hypertension. Hypovitaminosis D was the most
powerful predictor of the prevalence of dyslipidemia and
hypertension. GHD patients have an increased prevalence
of hypovitaminosis D compared with controls. The pres-
ence of hypovitaminosis D was the most powerful predictor
of the prevalence of dyslipidemia and hypertension in
GHD patients, suggesting the involvement of both factors
in the CV risk in these patients.
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Introduction
Currently, vitamin D deficiency represents one of the
environmental risk factors for the onset and progression of
various diseases. Thus, in addition to the well-known role
of vitamin D in the regulation of calcium and phosphorus
homeostasis and consequences of vitamin D deficiency on
the musculoskeletal system, nonskeletal effects of vitamin
D have been recognized [1]. More specifically, a growing
body of evidence suggests that vitamin D deficiency may
represent an important cardiovascular (CV) risk factor [1–
3]. The relationship between vitamin D and the CV system
is confirmed by evidence that vitamin D receptors are
present in most tissues including endothelium [4], vascular
smooth muscle [5], and myocardium [6]. Low vitamin D
status has been associated with an increase in blood pres-
sure (BP), adverse lipid profiles, impaired insulin meta-
bolism, and an increase in CV risk [7]. Low serum vitamin
D levels have been documented in patients with myocardial
infarction [8], stroke [9], congestive heart failure [10],
peripheral vascular insufficiency [11], type 2 diabetes
mellitus (DM), insulin resistance, obesity, and metabolic
syndrome (MS) [12, 13]. Several mechanisms have been
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proposed to explain the link between vitamin D and CV
disease [14], although this association remains to be con-
firmed [15]. On the other hand, abnormalities of the growth
hormone (GH)/insulin-like growth factor-I (IGF-I) axis
contribute in determining CV disease, as reported by sev-
eral clinical studies. Increased risk for CV morbidity and
mortality has been evidenced both in GH deficiency (GHD)
and excess [16, 17]. Epidemiological studies in the general
population have suggested that IGF-I levels in the lower
normal range are associated with an increased risk of
ischemic heart disease [18, 19], ischemic stroke [20, 21],
atherosclerosis [22, 23], severe hypertension, and type 2
DM [24]. Patients with hypopituitarism are known to have
reduced life expectancy with a 2-fold higher risk of death
for CV disease compared with healthy controls and GHD
has been considered the underlying factor of the increased
mortality when appropriate standard replacement of the
other pituitary hormones deficiencies is given [25, 26].
Recent findings suggested a relationship between GH/
IGF-I axis and vitamin D and this interplay occurs both at
endocrine and paracrine/autocrine levels [27, 28]. Vitamin
D regulates gene expression of the GH/IGF-I axis and may
promote the action of IGF-I by increasing IGF-I receptors,
and both GH and IGF-I can elevate vitamin D concentra-
tions by stimulating the hydroxylation in active hormone
form [27–30]. Probably, GH effects on modulating vitamin
D metabolism may be mediated by IGF-I and may be
independent of PTH [31]. Additionally, vitamin D may
enhance GH-dependent stimulation of IGF-I synthesis [32].
Few data are available regarding relationship between
GH/IGF-I axis and vitamin D in healthy subjects. However,
a positive association between vitamin D and IGF-I levels
has been found [33, 34]. Data in Italian healthy population
reported a clear relationship between vitamin D and serum
IGF-I levels, independent of confounding factors [35].
On the basis of these findings it can be assumed that a
state of hypovitaminosis D might contribute to increase the
CV risk in hypopituitaric patients with GHD. The aims of
the present study were first, to assess the prevalence of
hypovitaminosis D in hypopituitaric patients with GHD;
second, to correlate the hypovitaminosis D and GH/IGF-I
deficiency with CV risk parameters; lastly, to evaluate
which variable between presence of hypovitaminosis D and
GH/IGF-I deficiency was more strongly associated with
CV risk parameters.
Subjects and methods
Study population
Forty-one consecutive hypopituitaric patients with GHD
(22 males, 19 female, aged 18–84 years, mean age:
54.7 ± 15.4 years) admitted to the Department of Gas-
troenterology, Endocrinology and Surgery of the Univer-
sity ‘Federico II’ of Naples, Italy (latitude 40N) were
included in the study. Thirty-six patients had been previ-
ously operated on via the transsphenoidal and/or tran-
scranic route for non functioning pituitary adenoma (27
patients), craniopharyngioma (two patients), or other types
of pituitary tumor (two Ratke’s cleft cyst, two arachnoid
cyst, one ependymoma, one medulloblastoma, one
melanocytoma), and five patients had also been irradiated.
Five patients had idiopathic GHD. A variable degree of
pituitary insufficiency was found in our patients. The
patients with a previous diagnosis of acromegaly or
Cushing’s disease were excluded from the study. Before
being enrolled, in all patients hormone replacement therapy
with levothyroxine (50–100 mg/day), cortisone acetate
(25–37.5 mg/day), desmopressin acetate (5–20 mg/day),
testosterone-enanthate (250 mg i.m. monthly) in men and
oral or transdermal estrogens associated with progesterone
in premenopausal females was given as appropriate. Ade-
quacy of hormone replacement therapy was periodically
assessed by serum-free thyroid hormones, testosterone,
cortisol, urinary free cortisol, and serum and urinary
sodium and potassium measurements. At study entry, these
hormonal parameters were in the normal range for age in
all patients. None of the patients had ever received
recombinant human growth hormone (rhGH) treatment.
Dyslipidemia was found in 51.2 % of patients, type 2 DM
in 7.3 % and hypertension in 44 %. In addition, 17 % of
patients had MS according to the criteria by IDF [36].
Forty-one controls (22 males, 19 female, aged 21–84
years, mean age: 53.2 ± 16.0 years) comparable to patients
by sex, age, and body mass index (BMI), were also
included in the study. In all controls, GHD was excluded
by arginine (ARG) ? GH releasing hormone (GHRH) test.
Dyslipidemia was found in 12.1 % of controls, type 2 DM
in 17 %, hypertension in 22 % and MS in 14.6 %. The
clinical characteristics of patients and controls are shown in
Table 1.
Clinical assessment
At study entry, height, weight, waist circumference, BMI,
systolic blood pressure (SBP), and diastolic blood pressure
(DBP) were evaluated by standard methods in all patients
and controls. Waist circumference was measured to the
nearest 0.1 cm by using nonstretchable measuring tape
with the subjects standing in a relaxed position and arms at
the side. The measurement was taken at the midpoint
between the lower rib margin (12th rib) and the iliac crest.
BP was measured at the right arm, with subjects in a
relaxed sitting position. The average of two measurements
with a mercury sphygmomanometer was used.
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Use of specific treatment for dyslipidemia, type 2 DM
and hypertension was also recorded. Dyslipidemia was
considered when subjects had least two of the following
lipid alterations: high serum levels of total cholesterol and/
or high serum levels of low density lipoprotein (LDL)
cholesterol and/or high levels of triglycerides and/or
specific treatment for lipid abnormalities. MS was evalu-
ated by the IDF criteria [36]. Then, MS was considered
when the subject had central obesity, as assessed by waist
circumference[94 cm in males e[ 80 cm in female, in
addition at least two of the following factors: triglycerides
levels [150 mg/dL or specific treatment for this lipid
abnormality, high density lipoprotein (HDL) cholesterol
levels\40 mg/dL in males and\50 mg/dL in female or
specific treatment for this lipid abnormality, blood pressure
values [130/85 mm/Hg or treatment of previously diag-
nosed hypertension; fasting glucose levels[100 mg/dL or
previously diagnosed type 2 DM.
Biochemical assessment
In all patients and controls, routine blood tests including
total cholesterol, HDL cholesterol, LDL cholesterol,
triglycerides, glycemia, glycated hemoglobin (HbA1c),
insulin, creatinine, albumin, total alkaline phosphatase
(ALP), calcium, and phosphorus were determined on serum
samples at fasting by automated techniques (Roche
Modular System). Urinary calcium, phosphorus, and crea-
tinine were also measured on 24-h urine samples. Intact
parathyroid hormone (PTH) was measured by immuno-
metric assay (Immulite iPTH; Diagnostic Products, Los
Angeles, CA). 25(OH) vitamin D (vitamin D) is the vita-
min D metabolite that is measured to assess a patient’s
vitamin D status. Serum levels of vitamin D were measured
with chemiluminescence (Liaison, DiaSorin, Saluggia,
Italy). Vitamin D deficiency was defined as a serum con-
centration of vitamin D\20 ng/mL (50 nmol/L), insuffi-
ciency between 21 and 29 ng/mL (52.5–72.5 nmol/L) and
normal levels for values [30 ng/mL ([75 nmol/L) [37].
We defined as hypovitaminosis D when subjects had
vitamin D deficiency or vitamin D insufficiency defined by
serum vitamin D levels \30 ng/mL. In order to avoid
seasonal influences on vitamin D, the study has been car-
ried out from the beginning of November, 2013 to the end
of February, 2014. All patients and controls were tested
with ARG ? GHRH test. ARG (arginine hydrochloride,
SALF, Bergamo, Italy) was administered at the dose of
0.5 g/kg, up to a maximal dose of 30 g slowly infused from
time 0–30 min while GHRH (GHRH Ferring, Milan, Italy)
as given at the dose of 1 lg/kg as i.v. bolus at time 0.
Blood samples were taken every 30 min from 0 up to
60 min. The GH response after ARG ? GHRH was clas-
sified according with appropriate diagnostic cut-off limits
related to BMI [38]. Serum GH levels were measured by
immunoradiometric assay using commercially available
kits. The sensitivity of the assay was 0.2 lg/L. The intra-
and inter-assay coefficients of variation (CVs) were 4.5 and
7.9 %, respectively. Plasma IGF-I was measured by
immunoradiometric assay after ethanol extraction. The
normal ranges in 20–30, 31–40, 41–50, and over 50-yr-old
subjects were 110–502, 100–494, 100–303, and
78–258 mg/L, respectively. The sensitivity of the assay
was 0.8 mg/L. The intra-assay CVs were 3.4, 3.0, and
1.5 % for the low, medium, and high points of the standard
curve, respectively. The inter-assay CVs were 8.2, 1.5, and
3.7 % for the low, medium, and high points of the standard
Table 1 Clinical characteristics
of patients and controls
Patients Controls p
Male/female 22/19 22/19
Age (years) 54.7 ± 15.4 53.2 ± 16.0 0.668
BMI (Kg/m2) 27.6 ± 6.3 26.8 ± 5.8 0.881
GH peak after GHRH ? ARGININE (mcg/L) 2.5 ± 2.4 30.6 ± 6.3 \0.001
IGF-I (lg/L) 74.5 ± 37.2 158.4 ± 44.8 \0.001
Type 2 diabetes mellitus 7.3 % 17 % 0.292
Hypertension 44 % 22 % 0.060
Dyslipidemia 51.2 % 12.1 % \0.001
Metabolic syndrome 17 % 14.6 % 0.957
Multiple anterior pituitary deficiencies:
FSH/LH 46.3 % –
TSH 60 % –
ACTH 63 % –
Diabetes insipidus 22 % –
BMI body mass index, GH growth hormone, GHRH growth hormone releasing hormone, IGF-I insulin-like
growth factor-I
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curve. Since IGF-I levels are related to age, to analyze the
relationships between IGF-I levels and the other variables
we calculated the standard deviation score (SDS) of IGF-I
(zIGF-I) levels according to age [39]. To this aim, we
calculated the mean and SD of IGF-I levels in our subjects.
The zIGF-I for age and gender was also calculated
according to our population reference values. For the
purpose of this study, IGF-1 levels were classified as
‘‘normal’’ when higher than -1.5 SD, ‘‘insufficient’’ when
were between -1.5 and -2 SD and ‘‘deficient’’ when
lower than -2 SD [39–41]. In patients, serum testosterone,
estradiol, free thyroid hormones, TSH, FSH, LH, PRL, and
free urinary cortisol were measured by commercially
available immunoassays.
Statistical analysis
The statistical analysis was performed by SPSS for Win-
dows version 17 (SPSS Inc., Chicago, IL). Data were
expressed as mean ± standard deviation. ANOVA fol-
lowed by Newman-Keuls test for comparison between
groups has been used. The normality was assessed with
Kolmogorov–Smirnov test. The correlation analysis by
Pearson’s coefficient was assessed to study the correlation
between numerical data. The percentage of hypovita-
minosis, dyslipidemia, type 2 DM, hypertension and MS in
patients and controls were compared using v2-test. Using
glucocorticoid replacement and age as covariates, a linear
logistic regression analysis model (enter method) was
performed to determine if the categorical values of zIGF-I
and the presence of hypovitaminosis D were associated
with the presence of dyslipidemia, type 2 DM, hyperten-
sion and MS. A multinomial logistic regression analysis
model was also performed to evaluate which variable
between categorical values of zIGF-I and the presence of
hypovitaminosis D was more strongly associated with the
presence of dyslipidemia, hypertension, and MS. The limit
of significance was considered 5 %.
Results
IGF-I and vitamin D
Serum IGF-I concentrations were lower in patients than in
controls (p\ 0.001, Table.1), as expected. Particularly,
zIGF-I was between -1.5 and -2 SD in 19 patients
(46.3 %), below -2 SD in seven patients (17 %), and in
none of controls (p\ 0.001). The vitamin D levels were
lower in patients than in controls (21.3 ± 12.3 ng/mL
versus 28.2 ± 9.4, p = 0.006). In particular, vitamin D
deficiency (\20 ng/mL) was found in 51 % of patients
versus 14.6 % of controls (v2 = 9.07, p\ 0.01), insuffi-
ciency (21–29 ng/mL) in 26.8 versus 41.4 % (v2 = 0.03,
p = 0.269) and normal vitamin D levels ([30 ng/mL) in
21.9 versus 43.9 % (v2 = 3.53, p = 0.060) (Table 2).
Serum levels of PTH and serum and urinary levels of
calcium and phosphorus were similar in two groups (data
not shown).
CV risk parameters
No significant difference was found in glucose, insulin,
HbA1c and total cholesterol levels between patients and
controls (Table 2). HDL cholesterol levels were lower
(p = 0.002), whereas LDL cholesterol (p = 0.021) and
triglycerides (p = 0.002) levels were higher in patients
than in controls (Table 2). No significant difference was
Table 2 Cardiovascular risk
parameters and vitamin D status
in patients and in controls
Patients Controls p
Glycemia (mg/dL) 91.9 ± 16.1 87.6 ± 8.3 0.127
Insulin (lU/mL) 11.1 ± 7.5 12.2 ± 8.2 0.528
HbA1c (%) 5.8 ± 0.7 6.0 ± 1.2 0.359
Total cholesterol (mg/dL) 198.0 ± 38.0 185.5 ± 27.8 0.103
HDL cholesterol (mg/dL) 54.9 ± 18.2 75.1 ± 35.9 0.002
LDL cholesterol (mg/dL) 118.4 ± 25.9 106.3 ± 20.9 0.021
Triglycerides (mg/dL) 142.7 ± 65.5 103.5 ± 44.5 0.002
SBP mm/Hg 134.9 ± 18.7 136.7 ± 17.1 0.653
DBP mm/Hg 78 ± 8.7 78.4 ± 10.7 0.854
Vitamin D status:
Deficiency (\20 ng/mL) 51 % 14.6 % \0.01
Insufficiency (21–29 ng/mL) 26.8 % 41.4 % 0.269
Normal ([30 ng/mL) 21.9 % 43.9 % 0.060
HbA1c glycated hemoglobin, HDL high density lipoprotein, LDL low density lipoprotein, SBP systolic
blood pressure, DBP diastolic blood pressure
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found in SBP and DBP between patients and controls
(Table 2).
The prevalence of dyslipidemia was 51.2 % in patients
versus 12.1 % in controls (v2 = 12.67, p\ 0.001), type 2
DM was 7.3 versus 17 % (v2 = 1.02, p = 0.292), hyper-
tension was 44 versus 22 % (v2 = 3.53, p = 0.060) and
MS was found 17 % versus 14.6 % (v2 = 0.00, p = 0.957)
(Table 1).
Correlation study
A significant correlation was found between IGF-I and
vitamin D levels in patients and controls (r = 0.695,
p\ 0.001 and r = 0.492, p = 0.001, respectively). In
addition, in both patients and controls IGF-I and vitamin D
levels were correlated with age (IGF-I: r = -0.475,
p = 0.002; r = -0.863, p\ 0.001; vitamin D:
r = -0.295, p = 0.051; r = -0.333, p = 0.036; respec-
tively) and SBP (IGF-I: r = -0.609, p\ 0.001;
r = -0.608, p = 0.001; vitamin D: r = -0.412,
p = 0.009; r = –0.427, p = 0.033; respectively). In
patients, at linear regression analysis, the presence of
hypovitaminosis D and the prevalence of dyslipidemia,
hypertension and MS were significantly associated,
whereas no association was found between the presence of
hypovitaminosis D and the prevalence of type 2 DM
(Table 3). In addition, using glucocorticoid replacement
and age as covariates, the presence of hypovitaminosis D
and the prevalence of dyslipidemia (Exp(B):3.45, p:0.039),
hypertension (Exp(B):6.30, p:0.048) and MS (Exp(B):1.10,
p:0.012) remained significantly associated. A significant
association was also found between categorical value of
zIGF-I and the prevalence of hypertension (Table 3). No
associations were found between the presence of hypovi-
taminosis D and categorical value of zIGF-I with the
prevalence of dyslipidemia, hypertension, MS, and type 2
DM in controls (Table 3). At multinomial logistic regres-
sion analysis, in a model including as dependent variables
the prevalence of dyslipidemia, hypertension, and MS and
as covariates the categorical value of zIGF-I and the
presence of hypovitaminosis D in patients, the most pow-
erful predictor of the prevalence of dyslipidemia and
hypertension was the presence of hypovitaminosis D
(Table 4).
Discussion
The results of our study indicate that there is a high
prevalence of hypovitaminosis D (\30 ng/mL) in a repre-
sentative sample of 41 hypopituitaric patients with GHD, in
appropriate standard replacement for all pituitary hormones
deficiencies, except that GHD. In particular, vitamin D
deficiency was found 51 % in patients versus 14.6 % in
controls (p\ 0.01), insufficiency in 26.8 versus 41.4 %
(p = 0.269) and normal vitamin D levels in 21.9 versus
43.9 % (p = 0.060). In GHD patients, the presence of
hypovitaminosis D is the most powerful predictor of the
prevalence of dyslipidemia and hypertension.
Table 3 Linear regression analysis in patients and controls
Dyslipidemia Patients Controls
Exp (B) p Exp (B) p
Versus
Hypovitaminosis D 10.2 0.016 0.99 0.970
zIGF-I 0.26 0.084 1.02 0.129
Hypertension Patients Controls
Exp (B) p Exp (B) p
Versus
Hypovitaminosis D 8.00 0.004 0.47 0.339
zIGF-I 7.33 0.020 1.00 0.363
Metabolic syndrome Patients Controls
Exp (B) p Exp (B) p
Versus
Hypovitaminosis D 0.18 0.020 0.88 0.894
zIGF-I 0.26 0.123 0.98 0.319
Type 2 Diabetes mellitus Patients Controls
Exp (B) p Exp (B) p
Versus
Hypovitaminosis D 2.0 0.580 1.60 0.576
zIGF-I 0.92 0.950 1.02 0.794
zIGF-I standard deviation score (SDS) of IGF-I (zIGF-I)
Table 4 Multinomial logistic regression analysis in patients
Dyslipidemia Patients
Exp (B) p
Versus
Hypovitaminosis D 4.58 0.046
zIGF-I 0.57 0.511
Hypertension Patients
Exp (B) p
versus
Hypovitaminosis D 0.195 0.037
zIGF-I 0.279 0.177
zIGF-I standard deviation score (SDS) of IGF-I (zIGF-I)
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Recent findings report a relationship between GH/IGF-I
axis and vitamin D [27–32]. However, only few data are
available regarding relationship between GH/IGF-I axis
and vitamin D in general population [33–35]. Data col-
lected from 6810 British white subjects in the 1958 cohort,
surveyed during 2002–2004 (aged 45 years), evidenced a
positive association between vitamin D and IGF-I, with a
linear increase in IGF-1 until vitamin D concentrations
reached 75–85 nmol/L (30–34 ng/mL), after which this
effect reached a plateau [34]. More recently, data on a
cohort of Italian healthy adults showed a clear relationship
between vitamin D and serum IGF-I levels, independent of
confounding factors, including age, suggesting that vitamin
D status may contribute to circulating IGF-I levels in this
population [35]. The possible role of vitamin D on IGF-I
levels was supported by lower IGF-I levels in subjects with
severe vitamin D deficiency than in those with mild-to-
absent deficit, defined in this study by serum vitamin D
levels \20 ng/mL and C20 ng/mL, respectively [35]. In
line with this study, we also found a significant positive
correlation between vitamin D and IGF-I in both patients
and controls (r = 0.695, p\ 0.001 and r = 0.492,
p = 0.001; respectively). In this context, recent data in
GHD patients on replacement therapy with rhGH, evi-
denced that a better vitamin D status may ease the
achievement of normal IGF-I values, allowing the use of
lower doses of rhGH [42].
In our study, we also correlated the GH/IGF-I deficiency
and hypovitaminosis D with CV risk factors. As expected,
the prevalence of dyslipidemia was higher in patients than
in controls, while there were no differences in the preva-
lence of type 2 DM, hypertension and MS between patients
and controls. A possible explanation might be that both
patients and sex, age, and BMI-matched controls have been
recruited consecutively in this study and were all resident
in southern Italy, where the prevalence of type II DM,
overweight/obesity and MS is higher than in other regions.
In our patients a significant association was found
between the presence of hypovitaminosis D and the preva-
lence of dyslipidemia, hypertension and MS, whereas no
association was found between the presence of hypovita-
minosis D and the prevalence of type 2 DM. As well known,
age is tightly related to vitamin D status, while corticos-
teroids are able to increase the catabolism of vitamin D [43,
44]. However, also after adjusting for age and glucocorticoid
replacement, the association between the presence of
hypovitaminosis D and the prevalence of dyslipidemia,
hypertension, and MS remained significant, being the pres-
ence of hypovitaminosis D the most powerful predictor of
the prevalence of dyslipidemia and hypertension. Regarding
zIGF-I, a significant association was found only with the
prevalence of hypertension. It is known that abnormalities of
the GH/IGF-I axis contribute in determining CV disease, as
reported by several clinical studies. IGF-I levels in the lower
normal range are associated with an increased risk of
ischemic heart disease [18, 19], ischemic stroke [20, 21],
atherosclerosis [22, 23], severe hypertension and DM [24].
Patients with hypopituitarism are known to have reduced life
expectancy, with a 2-fold higher risk of death for CV disease
compared with healthy controls, and GHD has been con-
sidered the underlying factor of the increased mortality also
when appropriate standard replacement of the other pituitary
hormones deficiencies is given [25, 26].
On the other hand, it has been suggested that low vitamin
D status may represent an important CV risk factor [1–4, 7].
Low serum levels of vitamin D have been associated with
an adverse lipid profile, with lower HDL cholesterol, higher
triglycerides, higher apolipoprotein E levels, and hyperc-
holesterolemia [45–47]. However, data on association
between vitamin D status and lipid profile are still lacking
and this association remains unclear. In a recent large
clinical trial in postmenopausal women, using data from the
Women’s Health Initiative, the authors evaluated the long-
term effect of calcium and vitamin D supplementation on
circulating concentrations of lipid and found no significant
effects on changes in lipid concentrations [48].
Vitamin D has been also reported to be involved in BP
regulation. Patients who live at higher latitudes and are
considered to be at higher risk of vitamin D deficiency are
more likely to develop hypertension [49]. Lower vitamin D
levels have been associated with high BP and hypertension
risk [7, 50, 51]. The finding that vitamin D negatively
regulates the renin-angiotensin axis could explain the link
between hypovitaminosis D and BP [52]. However, some
studies have failed to find an association [53]. Recent trial
data have shown no significant effect of vitamin D sup-
plementation on blood pressure, even at high doses, low
vitamin D levels and in patients with high baseline blood
pressure [54].
Finally, hypovitaminosis D also appears to be related to
the MS and its component, such as obesity and insulin
resistance [55]. Interestingly, Hypponen et al. [34] exam-
ined the associations of both vitamin D status and IGF-I
with MS and its individual components (abdominal obe-
sity, HbA1c, high BP, low HDL cholesterol, high triglyc-
erides) in nearly 7000 participants at age 45 years. The
examination of the interactions between these factors fur-
ther suggested that vitamin D was inversely associated with
MS, regardless of IGF-I concentration, whereas the inverse
association with IGF-1 was found only among those
without hypovitaminosis D, suggesting that individual’s
vitamin D status was essential for the metabolic effects of
IGF-I.
There are some limitations in the present study. In
particular, from an epidemiological point of view, GHD is
a rare disease. This limits the number of available patients
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and there is need for caution in the interpretation of the
results of this study. Moreover, the group of hypopituitaric
GHD patients enrolled in this study is heterogenous and
include patients with previous radiotherapy and patients on
multiple hormonal replacement therapies which may affect
the CV risk.
Conclusion
In summary, the results of the present study indicate that
the GHD hypopituitaric patients have an increased preva-
lence of hypovitaminosis D compared with controls. The
presence of hypovitaminosis D is the most powerful pre-
dictor of the prevalence of dyslipidemia and hypertension.
Although in GHD hypopituitaric patients, CV risk and
mortality are influenced by other factors, such as excessive
glucocorticoids or T4 replacement, gonadal steroids under-
replacement, and previous radiotherapy, the hypovita-
minosis D might be also considered as adjunctive CV risk
factor in these patients.
Nonetheless, due to paucity of intervention studies, a
causal link between vitamin D status and CV disease in
GHD hypopituitaric patients is far from be proven, thus no
guidance can be provided for or against recommending
vitamin D supplementation for prevention or treatment of
CV disease in these patients. Ongoing and future trials are
expected to provide answers to whether vitamin D sup-
plementation holds promise for the prevention of CV dis-
ease in GHD hypopituitaric patients and for a better
management of these patients.
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